HealthQuill US
AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services and peptide-based drug discovery, for about $2.2 billion to mark its entry into the obesity treatment space.
Drugs Medical Pharma

AbbVie inks $2.2b deal with Denmark’s Gurba, enters weight-loss market

 HQ Team March 4, 2025: AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services.

Read More
Eli Lilly will set up four new pharmaceutical manufacturing facilities in the US for $27 billion to further bolster its supply chains, according to a statement.
Drugs Medical Pharma

Eli Lilly to set up four manufacturing facilities in US for $27 billion

Eli Lilly will set up four new pharmaceutical manufacturing facilities in the US for $27 billion to further bolster its supply chains, according.

Read More
The World Health Organization is crowdsourcing to fund its health programs by urging individuals globally to donate to the ‘1 Dollar 1 World movement’ initiative.
Drugs Health Medical

WHO Foundation to crowdsource funds for global health programmes

The World Health Organization is crowdsourcing to fund its health programs by urging individuals globally to donate to the ‘1 Dollar 1 World.

Read More
Eli Lilly cuts price of weight-loss drug Zepbound to take on copycats
Drugs Health Pharma

Eli Lilly cuts price of weight-loss drug Zepbound to take on copycats

Eli Lilly and Company cut the prices of its weight-loss drug  Zepbound, available in single-dose vials, in a bid to end compounding companies from.

Read More
Regeneron Pharmaceuticals, Inc.’s investigational gene therapy improved hearing in 10 out of 11 children born with hearing loss because of gene mutation, according to a company statement.
Drugs Health Medical

Regeneron’s trial therapy improves hearing in children with gene mutations

Regeneron Pharmaceuticals, Inc.’s investigational gene therapy improved hearing in 10 out of 11 children born with hearing loss because of gene mutation, according.

Read More
Saudi Arabia has reaffirmed a $500 million pledge to the WHO’s Global Polio Eradication Initiative to fight the disease plaguing vulnerable children, according to a statement.
Health Medical Pharma

Saudi Arabia reaffirms $500 million pledge to eradicate polio

Saudi Arabia has reaffirmed a $500 million pledge to the WHO’s Global Polio Eradication Initiative to fight the disease plaguing vulnerable children, according.

Read More
US-based private equity and advisory investment firm KKR & Co. Inc. will pay CVC Capital Partners $400 million to acquire a majority stake in India’s HealthCare Global Enterprises Ltd. (HCG).
Health Medical Pharma

KKR to acquire majority stake in India’s HCG for $400 million

US-based private equity and advisory investment firm KKR & Co. Inc. will pay CVC Capital Partners $400 million to acquire a majority stake.

Read More
Mirum Pharmaceuticals Inc.’s oral cholesterol drug for treating a rare metabolic disease has been approved by the Food and Drug Administration.
Drugs Health Medical

US regulator clears Mirum’s oral drug for reducing cholesterol deposits

Mirum Pharmaceuticals Inc.’s oral cholesterol drug for treating a rare metabolic disease has been approved by the Food and Drug Administration.

Read More
The international humanitarian aid system of the United Nations, set up after the Second World War, is facing the “greatest test since creation” due to low morale, poor funding and a legitimacy crisis, a UN official said.
Health Medical Pharma

UN humanitarian aid system facing ‘greatest test’ since creation: Relief chief

The international humanitarian aid system of the United Nations, set up after the Second World War, is facing the “greatest test since creation”.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More